Abraham Getachew Kelbore | Deramtology | Innovative Research Award

Posted on by Skincare

Innovative Research Award

Abraham Getachew Kelbore – Wolaita Sodo University

Abraham Getachew Kelbore
Affiliation Wolaita Sodo University
Country Ethiopia
Scopus ID 56798540800
Documents 3024
Citations 3072
h-index 12
Subject Area Dermatology
Event World Skincare Innovation Awards
ORCID 0000-0001-9540-8671

Abraham Getachew Kelbore is an academic researcher and assistant professor specializing in tropical dermatology at Wolaita Sodo University, Ethiopia. His scholarly work focuses on skin diseases, neglected tropical diseases, and quality-of-life studies among dermatology patients. Through clinical research and community engagement, he has contributed to improving dermatological care in underserved regions. His research profile demonstrates active international collaboration and sustained scientific productivity.[1]

Abstract

This article summarizes the scholarly achievements of Abraham Getachew Kelbore in dermatology and tropical medicine. His research emphasizes evidence-based interventions, epidemiology of skin diseases, and healthcare accessibility in Ethiopia. The body of work demonstrates multidisciplinary collaboration and international visibility in peer-reviewed literature. These contributions support recognition within global dermatological research communities.[2]

Keywords

Dermatology, Tropical Medicine, Atopic Dermatitis, Skin Diseases, Ethiopia, Public Health, Neglected Tropical Diseases.

Introduction

Research in dermatology contributes significantly to disease prevention and quality-of-life improvement. Abraham Getachew Kelbore has focused on tropical skin disorders and healthcare delivery in resource-limited settings. His work bridges clinical practice, research, and community health initiatives. Such contributions align with broader public health priorities in Africa and beyond.[3]

Research Profile

Kelbore serves as Assistant Professor of Dermatology at Wolaita Sodo University and has extensive teaching experience. His interests include atopic dermatitis, neglected tropical diseases, and dermatological epidemiology. He has collaborated with international institutions and contributed to expanding dermatology services. His academic record reflects continued engagement in research and clinical innovation.[1]

Research Contributions

Major contributions include studies on atopic dermatitis, scabies prevalence, cutaneous leishmaniasis, and HIV-related skin disorders. His research has informed clinical practice and strengthened disease surveillance efforts. Several studies emphasize healthcare access and patient quality of life. These works demonstrate measurable relevance to global dermatology research.[4]

Publications

  • Impact of Atopic Dermatitis on the Quality of Life of Children in Ethiopia (2026).
  • The impact of atopic dermatitis on caregivers’ quality of life in Ethiopia (2025).
  • Atopic dermatitis in Ethiopian children: multicenter study (2024).
  • Scabies prevalence among prisoners in southern Ethiopia (2023).
  • Pattern of skin diseases in children attending dermatology clinics (2019).

Research Impact

The researcher’s publications have contributed to evidence generation in dermatology and public health. Citation metrics and international collaborations indicate growing academic influence. His work supports healthcare policy development and clinical decision-making in tropical settings. The research outputs remain relevant to practitioners and scholars worldwide.[5]

Award Suitability

The research profile demonstrates sustained productivity, international engagement, and societal relevance. Contributions to neglected tropical diseases and dermatology services illustrate measurable public health impact. These characteristics align with criteria commonly used for innovation and research awards. Recognition through the World Skincare Innovation Awards would acknowledge such achievements.

Conclusion

Abraham Getachew Kelbore has established a significant research presence in dermatology and tropical medicine. His scientific contributions address pressing healthcare challenges in Ethiopia and internationally. Continued scholarship and collaboration may further strengthen dermatological research capacity. The academic record supports professional recognition in global research forums.

External Links

References

  1. Kelbore, A. G., Enbiale, W., van Wyk, J. M., Bogino, E. A., Morrone, A., & Mosam, A. (2026). Impact of atopic dermatitis on the quality of life of children in Ethiopia: A multicenter prospective cohort study. Children. 
    https://doi.org/10.3390/children13020201
  2. Kelbore, A. G., Enbiale, W., van Wyk, J. M., & Mosam, A. (2024). Atopic dermatitis in Ethiopian children: A multicenter study of clinical severity, characteristics, and sociodemographic factors. Frontiers in Medicine. 
    https://doi.org/10.3389/fmed.2024.1410310
  3. Bogino, E. A., Beebe, N., Woldegeorgis, B. Z., Wondewosen, L., Dessu, B. K., Obsa, M. S., … & Kelbore, A. G. (2023). Scabies prevalence and its associated factors among prisoners in southern Ethiopia: An institution-based analytical cross-sectional study. PLOS Neglected Tropical Diseases. 
    https://doi.org/10.1371/journal.pntd.0011826
  4. Kelbore, A. G., Enbiale, W., Mosam, A., & van Wyk, J. M. (2022). Mapping research evidence on quality of life in children with atopic dermatitis in sub-Saharan Africa: A scoping review protocol. Systematic Reviews. 
    https://doi.org/10.1186/s13643-022-02133-w
  5. Kelbore, A. G., Owiti, P., Reid, A. J., Bogino, E. A., Wondewosen, L., & Dessu, B. K. (2019). Pattern of skin diseases in children attending a dermatology clinic in a referral hospital in Wolaita Sodo, southern Ethiopia. BMC Dermatology, 19, Article 8. 
    https://doi.org/10.1186/s12895-019-0085-5

Hui Xiong | Pharmaceutics | Best Researcher Award

Posted on by Skincare

Dr. Hui Xiong | Pharmaceutics | Best Researcher Award
Associate Professor | China Pharmaceutical University | China

Dr. Hui Xiong is an Associate Professor in the Department of Pharmaceutics at China Pharmaceutical University, where she leads pioneering research in advanced drug delivery systems and nanomedicine engineering. She earned her Ph.D. in Pharmaceutics and has since focused her career on the rational design of multifunctional nanocarriers to improve the bioavailability, targeting precision, and therapeutic index of anticancer drugs. Her work integrates pharmaceutics, tumor biology, and materials science to develop innovative delivery platforms for combination therapy, pH-activated antiangiogenic chemotherapy, tumor microenvironment modulation, and ferroptosis-inducing therapeutic strategies, with a strong emphasis on breast and pancreatic cancer treatment. Dr. Xiong has published over 30 SCI papers as first or corresponding author in leading journals such as ACS Nano, Nano Letters, Journal of Controlled Release, Small, and Advanced Healthcare Materials, accumulating a total impact factor exceeding 188 and an H-index of 16. Her contributions include groundbreaking studies on vascular normalization, metabolic symbiosis-blocking nanocombinations, bioengineered nanospores for macrophage modulation, and redox-regulated nanodrugs, several of which have been featured on journal covers. She has been the principal investigator for multiple National Natural Science Foundation of China projects and holds four national invention patents, advancing translational pharmaceutics for clinical oncology. Recognized for her contributions to cancer nanomedicine, she also serves as a peer reviewer for several high-impact journals, further shaping the direction of pharmaceutics and targeted drug delivery research. 

Profile : ORCID

Publications

1. He, Z., Wang, R., Qi, Y., Liu, Y., Xiong, H.*, & Yao, J. (2024). Nanocoated bacteria with H₂S generation-triggered self-amplified photothermal and photodynamic effect for breast cancer therapy. Journal of Controlled Release.

2. Qiao, J., Liu, S., Huang, Y., Zhu, X., Xue, C., Wang, Y., Xiong, H.*, & Yao, J. (2024). Glycolysis–noncanonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment. Journal of Colloid and Interface Science.

3. Yao, L., Zhu, X., Shan, Y., Zhang, L., Yao, J., & Xiong, H.* (2024). Recent progress in anti-tumor nanodrugs based on tumor microenvironment redox regulation. Small.

4. Shang, Y., Lu, H., Liao, L., Li, S., Xiong, H.*, & Yao, J. (2023). Bioengineered nanospores selectively blocking LC3-associated phagocytosis in tumor-associated macrophages potentiate antitumor immunity. ACS Nano.

5. Xiong, H., Liu, X., Xie, Z., Zhu, L., Lu, H., Wang, C., & Yao, J. (2022). Metabolic symbiosis-blocking nanocombination for tumor vascular normalization treatment. Advanced Healthcare Materials.